In tumour cells, for instance, the loss of classical HLA-I expression would provide a survival advantage, but the subsequent reduction in availability of leader peptides, along with the co-regulation, determines a decrease in HLA-E presentation: this removes signals that are inhibitory for NK cells, licensing them to kill the target tumour cells. This evidence concerns the gene HLA-E and neoplasm.